

Tigecycline:

Class: Antibiotic.

Indications:

Treatment of complicated skin and skin structure infections caused by susceptible organisms, including methicillin-resistant *Staphylococcus aureus* and vancomycin-sensitive *Enterococcus faecalis*; complicated intra-abdominal infections (cIAI); community-acquired pneumonia.

Available dosage form in the hospital: 50MG VIAL.

Dosage:

-Pneumonia, community-acquired: I.V.: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 7-14 days

-Intra-abdominal infections, complicated (cIAI): I.V.: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 5-14 days; **Note:** 2010 IDSA guidelines recommend treatment duration of 4-7 days (provided source controlled) for community-acquired, mild-to-moderate IAI

-Skin/skin structure infections, complicated: I.V.: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 5-14 days

Renal Impairment:

-No dosage adjustment required in renal impairment.

-Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).

Hepatic Impairment:

-Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment required.

-Severe hepatic impairment (Child-Pugh class C): Initial: 100 mg single dose; Maintenance: 25 mg every 12 hours.

Common side effect:

Gastrointestinal: Nausea , vomiting , diarrhea , Abdominal pain.

Central nervous system: Headache ,dizziness .

Dermatologic: Rash .

Endocrine & metabolic: Hypoproteinemia .

Hepatic: ALT increased , AST increased , alkaline phosphatase increased .

Pregnancy Risk Factor :D